FDA Alerts
FDA Approves Lenvima for a Type of Thyroid Cancer
The U.S. Food and Drug Administration today granted approval to Lenvima (lenvatinib) to treat patients with progressive, differentiated thyroid cancer (DTC) whose disease progressed despite receiving radioactive iodine therapy (radioactive iodine refractory disease).
FDA Approves Nexavar to Treat Type of Thyroid Cancer
The U.S. Food and Drug Administration today expanded the approved uses of Nexavar (sorafenib) to treat late-stage (metastatic) differentiated thyroid cancer.
FDA approves Cometriq to treat rare type of thyroid cancer
The US Food and Drug Administration today approved Cometriq ( cabozantinib ) to treat medullary thyroid cancer that has spread to other parts of the body (metastasized).
FDA approves Erbitux to treat late-stage head and neck cancer
The U.S. Food and Drug Administration today approved Erbitux ( cetuximab ) for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer.
FDA Approves New Treatment for Rare Form of Thyroid Cancer
The U.S. Food and Drug Administration (FDA) today approved vandetanib to treat adult patients with late-stage (metastatic) medullary thyroid cancer who are ineligible for surgery and who have disease that is growing or causing symptoms.